Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Calreticulin Gene Mutations in Suspicion of Myeloproliferative Neoplasms: A Single Institution Experience

Amin Ben Lassoued, PharmD, Nathalie Beaufils, MSc, Caroline Bonnefoy, Jean Gabert, MD PhD

Blood (2014) 124 (21): 5569.

https://doi.org/10.1182/blood.V124.21.5569.5569

Published: 2014

Journal Articles

Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

Blood (2011) 117 (24): 6650–6659.

https://doi.org/10.1182/blood-2011-02-336842

Published: 2011

Includes: Supplemental data

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 4188.

https://doi.org/10.1182/blood.V116.21.4188.4188

Published: 2010

Journal Articles

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

Virginie Gandemer, MD, Marie-Françoise Auclerc, MD, Arnaud Petit, MD, Benoît Brethon, MD, Paola Ballerini, Gerard Michel, MD, PhD, Yves Perel, MD, PhD, Anne Auvrignon, MD, Francoise Mechinaud, Claudine Schmitt, Pascale Schneider, Christiane Vermylen, Odile Lejars, MD, Thierry Leblanc, MD, Jean Gabert, MD, PhD, Elizabeth Macintyre, MD, PhD, Jean-Michel Cayuela, PharmD, PhD, Guy Leverger, MD, Andre Baruchel, MD

Blood (2009) 114 (22): 1628.

https://doi.org/10.1182/blood.V114.22.1628.1628

Published: 2009

Journal Articles

The Use of ABL and GUS as Control Genes for Normalizing Quantification of Fusion Transcripts by Real Time PCR: Our Experience of More Than 1000 Samples.

Mohamed Amin Ben Lassoued, Nathalie Beaufils, Anderson Dieudonné Loundou, Christiane Arnaud, Jean Gabert, MD, PhD

Blood (2009) 114 (22): 4727.

https://doi.org/10.1182/blood.V114.22.4727.4727

Published: 2009

Journal Articles

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia (ALL) at Diagnosis and/or at First Relapse: Results from the GET-LALA Group.

Oumedaly Reman, MD, Arnaud Pigneux, MD, Francoise Huguet, MD, Norbert Vey, MD, Andre Delannoy, MD, Nathalie Fegueux, MD, Stephane de Botton, MD, Aspasia Stamatoullas, MD, Olivier Tournilhac, MD, Agnes Buzyn, MD, Christiane Charrin, MD, Claude Boucheix, MD, Jean Gabert, MD, Veronique Lheritier, CRA, Jean-Paul Vernant, MD, Denis Fiere, MD, Herve Dombret, MD, Xavier Thomas, MD

Blood (2007) 110 (11): 4326.

https://doi.org/10.1182/blood.V110.11.4326.4326

Published: 2007

Journal Articles

Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial.

Emmanuelle Tavernier, MD, Jean-Michel Boiron, MD, Francoise Huguet, MD, Kenneth Francis Bradstock, MD, Norbert Vey, MD, Tibor Kovacsovics, MD, Andre Delannoy, MD, Nathalie Fegueux, MD, Pierre Fenaux, MD, Aspasia Stamatoullas, MD, Olivier Tournilhac, MD, Agnes Buzyn, MD, Oumedaly Reman, MD, Christiane Charrin, MD, Claude Boucheix, MD, Jean Gabert, MD, Veronique Lheritier, CRA, Jean-Paul Vernant, MD, Xavier Thomas, MD

Blood (2006) 108 (11): 1876.

https://doi.org/10.1182/blood.V108.11.1876.1876

Published: 2006

Journal Articles

Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.

Thibaut Leguay, MD, Francis Witz, MD, Stéphane De Botton, MD, Jean Gabert, MD PHD, Jean-Michel Cayuela, MD PHD, Elizabeth Macintyre, MD PHD, Claude Preudhomme, MD, Nathalie Fegueux, MD, Xavier Thomas, MD, Jean-Yves Cahn, MD, Martine Escoffre, MD, Andre Delannoy, MD, Norbert Ifrah, MD, Herve Dombret, MD, Arnaud Pigneux, MD

Blood (2006) 108 (11): 1877.

https://doi.org/10.1182/blood.V108.11.1877.1877

Published: 2006

Journal Articles

New Detection Method of V617F JAK2 Mutation; Its Use in a Clinical Setting.

Delphine Chabas, Nathalie Beaufils, Gerard Sebahoun, Regis Costello, J. Weiller, Jean-Robert Harle, Jean Gabert

Blood (2006) 108 (11): 4889.

https://doi.org/10.1182/blood.V108.11.4889.4889

Published: 2006

Journal Articles

A 3′ RACE-PCR Method of Identification of Unknown MLL Gene Partner and Break-Point at RNA Level.

Christine Formisano-Tréziny, Fabienne Hermitte, Benoît Quilichini, Hervé Chambost, Gérard Michel, Jean Gabert

Blood (2006) 108 (11): 4275.

https://doi.org/10.1182/blood.V108.11.4275.4275

Published: 2006

Journal Articles

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Blood (2006) 108 (1): 28–37.

https://doi.org/10.1182/blood-2006-01-0092

Published: 2006

Journal Articles

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

André Baruchel, MD, Sylvie Chevret, MD, PhD, Anne Auvrignon, MD, Paola Ballerini, MD, PhD, Gérard Michel, MD, Jean Gabert, MD, PhD, Christiane Vermylen, MD, Yves Perel, MD, Chrystèle Bilhou-Nabera, MD, Odile Lejars, MD, Claudine Schmitt, MD, Pierre Jonveaux, MD, PhD, Jean Soulier, MD, PhD, Jacqueline Vandenaker, MD, Marie-Françoise Auclerc, MD, Thierry Leblanc, MD, Guy Leverger, MD, for the FRALLE Group

Blood (2005) 106 (11): 1441.

https://doi.org/10.1182/blood.V106.11.1441.1441

Published: 2005

Journal Articles

Evaluation of Minimal Residual Disease (MRD) by Quantification of TEL-AML1 Transcripts Is a Powerful Prognostic Tool in Children with T(12;21) Positive Acute Lymphoblastic Leukemia (ALL).

Blood (2004) 104 (11): 322.

https://doi.org/10.1182/blood.V104.11.322.322

Published: 2004

Journal Articles

Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.

Herve Dombret, Francis Witz, Stephane De Botton, Jean-Michel Cayuela, Eric Delabesse, Claude Preudhomme, Francoise Huguet-Rigal, Anne Vekhoff, Charles Dauriac, Sandrine Hayette, Norbert Vey, Xavier Thomas, Tibor Kovacsovics, Andre Delannoy, Amel Ouslimani, Elodie Soler, Jean Gabert, Elizabeth Macintyre, Jean-Paul Vernant

Blood (2004) 104 (11): 2741.

https://doi.org/10.1182/blood.V104.11.2741.2741

Published: 2004

Journal Articles

Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial

Blood (2002) 100 (7): 2357–2366.

https://doi.org/10.1182/blood-2002-03-0704

Published: 2002

Journal Articles

Prognosis Value of Residual Disease Monitoring by Polymerase Chain Reaction in Patients With CBFβ/MYH11-Positive Acute Myeloblastic Leukemia

Régis Costello, Danièle Sainty, Didier Blaise, Jean-Albert Gastaut, Jean Gabert

Blood (1997) 89 (6): 2222.

https://doi.org/10.1182/blood.V89.6.2222

Published: 1997

NARROW

Calreticulin Gene Mutations in Suspicion of Myeloproliferative Neoplasms: A Single Institution Experience

Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

The Use of ABL and GUS as Control Genes for Normalizing Quantification of Fusion Transcripts by Real Time PCR: Our Experience of More Than 1000 Samples.

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia (ALL) at Diagnosis and/or at First Relapse: Results from the GET-LALA Group.

Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial.

Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.

New Detection Method of V617F JAK2 Mutation; Its Use in a Clinical Setting.

A 3′ RACE-PCR Method of Identification of Unknown MLL Gene Partner and Break-Point at RNA Level.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

Evaluation of Minimal Residual Disease (MRD) by Quantification of TEL-AML1 Transcripts Is a Powerful Prognostic Tool in Children with T(12;21) Positive Acute Lymphoblastic Leukemia (ALL).

Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.

Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial

Prognosis Value of Residual Disease Monitoring by Polymerase Chain Reaction in Patients With CBFβ/MYH11-Positive Acute Myeloblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only